metastatic prostate cancer

Top 5 pipeline drugs for 2018New blockbuster drugs to treat various conditions are expected to be among the top drugs to hit the marketplace in 2018. Here are 5 of the top new drugs in the pipeline for 2018, according to analysts.
Anti-androgen shows benefit in pre-chemo setting
Anti-androgen shows benefit in pre-chemo settingThe second-generation androgen receptor antagonist enzalutamide (XTANDI) significantly improved survival and delayed the time to chemotherapy in men with previously untreated metastatic castrate-resistant prostate cancer, according to a recent study.
Prostate cancer agent meets key endpoints in pre-chemo setting
Prostate cancer agent meets key endpoints in pre-chemo settingA phase III trial of enzalutamide (Xtandi) in chemotherapy-naïve patients with advanced prostate cancer has met both of its primary endpoints in an interim analysis, and the trial will be stopped early due to the drug’s benefit.
Incidence of non-osseous metastatic prostate cancer on the riseNew therapies that are extending survival of men with metastatic castration-resistant prostate cancer may also be contributing to an increasing trend for the development of non-osseous metastatic disease in these patients, according to a recent study.
Test accurately forecasts metastatic prostate cancer post-radical prostatectomyA new prognostic test for prostate cancer outperformed existing risk assessment tools for predicting metastatic disease in patients following radical prostatectomy, researchers reported.